Cargando…
Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evoluti...
Autores principales: | Zhang, Zhendong, Cai, Bin, Sun, Yanzhuan, Deng, Haiyan, Wang, Hongwei, Qiao, Zengyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871785/ https://www.ncbi.nlm.nih.gov/pubmed/36704458 http://dx.doi.org/10.3389/fcvm.2022.1076806 |
Ejemplares similares
-
Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis
por: Fang, Chen, et al.
Publicado: (2022) -
Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis
por: Fu, Yuan, et al.
Publicado: (2022) -
Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke
por: Yu, Fang, et al.
Publicado: (2021) -
Interplay Between Gut Microbiota and Amino Acid Metabolism in Heart Failure
por: Tuerhongjiang, Gulinigaer, et al.
Publicado: (2021) -
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure
por: Zong, Xiao, et al.
Publicado: (2022)